



## Vaccine Adjuvants Research

Guest Editor:

### Prof. Dr. Olga Borges

Center for Neurosciences and Cell Biology (CNC), Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

Deadline for manuscript submissions:

**closed (31 July 2023)**

### Message from the Guest Editor

The appearance of the SARS-CoV-2 virus in 2020 brings, again, to public discussion, the importance of being prepared for the development of vaccines in a short period of time. Reverse vaccinology and proteomic approaches have allowed rapid identification of the antigenic structures and, thus, the design of a successful vaccine. A huge diversity of vaccines is being tested, based on RNA, DNA, recombinant proteins, inactivated and attenuated virus, and viral vectors. Appropriate adjuvants for these vaccines are not approved and need to be developed not only for injectable vaccines but, also, to obtain more stable, needle-free, oral, and intranasal vaccines. These last modalities would help to not only increase the vaccine coverage but also more rapidly, and to decrease the infections associated with bad clinical practice during the administration of injectables, especially in developing countries. The objective of this Special Issue of *Vaccines* is to cover the most recent developments in vaccine adjuvants and formulations.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)